United States — Food and Drug Administration & American Heart Association

United States — Food and Drug Administration: The United States — Food and Drug Administration's lack of regulation over supplements like Melatonin is highlighted as a concern, leading to variability in dosage and purity.

American Heart Association: The American Heart Association is presenting new research suggesting a link between long-term Melatonin use and heart failure, contributing to public health awareness.

United States — Food and Drug Administration: Regulatory body that approved Lipfendra, enabling market entry.

American Heart Association: Issued updated LDL cholesterol guidelines that support use of potent therapies like Lipfendra.

United States — Food and Drug Administration: The United States — Food and Drug Administration does not regulate Melatonin as a drug in the United States, which means manufacturers are not subject to the same scrutiny as prescription medications.

American Heart Association: The American Heart Association is the organization where the preliminary study on Melatonin's risks was presented and is involved in disseminating information about heart health.

United States — Food and Drug Administration: The United States — Food and Drug Administration is the regulatory body with whom Moderna will discuss the next randomized stage of development for SRD-002, making its involvement crucial for the therapy's future.

American Heart Association: The American Heart Association Scientific Sessions 2025 was where previous positive data from Moderna's Cohort A patients were reported, providing a platform for disseminating early clinical findings.

United States — Food and Drug Administration: Mentioned for caffeine intake recommendations, not directly involved.

American Heart Association: Mentioned for its added sugar intake recommendations, not directly involved.